HRP20210792T1 - Imunosupresivna sredstva i njihova uporaba u terapiji - Google Patents

Imunosupresivna sredstva i njihova uporaba u terapiji Download PDF

Info

Publication number
HRP20210792T1
HRP20210792T1 HRP20210792TT HRP20210792T HRP20210792T1 HR P20210792 T1 HRP20210792 T1 HR P20210792T1 HR P20210792T T HRP20210792T T HR P20210792TT HR P20210792 T HRP20210792 T HR P20210792T HR P20210792 T1 HRP20210792 T1 HR P20210792T1
Authority
HR
Croatia
Prior art keywords
seq
preparation
agent
kit
product
Prior art date
Application number
HRP20210792TT
Other languages
English (en)
Inventor
Marit Otterlei
Original Assignee
Norwegian University Of Science And Technology (Ntnu)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Norwegian University Of Science And Technology (Ntnu) filed Critical Norwegian University Of Science And Technology (Ntnu)
Publication of HRP20210792T1 publication Critical patent/HRP20210792T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Claims (15)

1. Sredstvo, ili pripravak koji sadrži sredstvo, za uporabu u liječenju hipercitokinemije kod subjekta što proizlazi iz oslobađanja citokina iz ne-proliferirajućih imunoloških stanica u krvi, pri čemu navedeno sredstvo sadrži: (i) oligopeptidni spoj koji sadrži PCNA motiv interakcije i peptid koji prodire u stanice (CPP), pri čemu je PCNA motiv interakcije X1X2X3X4X5 (SEQ ID NO: 2) i pri čemu: X1 je odabran između arginina (R), lizina (K) i histidina (H); X2 je odabran između triptofana (W), fenilalanina (F) i tirozina (Y); X3 je odabran između leucina (L), izoleucina (I), valina (V), alanina (A), metionina (M), serina (S), treonina (T), asparagina (N), glutamina (Q) i cisteina (C); X4 je odabran između valina (V), leucina (L), izoleucina (I), alanina (A), metionina (M), glicina (G), serina (S), treonina (T), asparagina (N), glutamina (Q), arginina (R), lizina (K), histidina (H) i cisteina (C); i X5 je odabran između arginina (R), lizina (K), histidina (H) i prolina (P); ili (ii) molekulu nukleinske kiseline koja sadrži sekvencu koja kodira oligopeptidni spoj iz (i).
2. Sredstvo ili pripravak za uporabu u skladu sa zahtjevom 1, naznačeno time što se navedeno sredstvo ili pripravak pruža kao kombinirani pripravak s jednim ili više dodatnih aktivnih sredstava za odvojenu, istodobnu ili sekvencijalnu uporabu ili primjenu.
3. Komplet ili proizvod koji sadrži sredstvo ili pripravak za uporabu kako je definirano u zahtjevu 1 i jedno ili više dodatnih aktivnih sredstava kao kombinirani pripravak za simultanu, sekvencijalnu ili odvojenu uporabu u liječenju hipercitokinemije kod subjekta što proizlazi iz oslobađanja citokina iz ne-proliferirajućih imunoloških stanica u krvi.
4. Sredstvo, pripravak, komplet ili proizvod za uporabu kako je definirano u bilo kojim od zahtjeva 1 do 3, naznačeni time što navedene ne-proliferirajuće imunološke stanice pokazuju receptor površine stanice CD14 i/ili receptor površine stanice CD16, poželjno gdje su navedene ne-proliferirajuće imunološke stanice monociti.
5. Sredstvo, pripravak, komplet ili proizvod za uporabu u skladu s bilo kojim od patentnih zahtjeva 2 do 4, naznačen time što je jedno ili više dodatnih aktivnih sredstava inhibitor kinaze, imunosupresivni spoj, protuupalni spoj, antimikrobni spoj ili steroid.
6. Sredstvo, pripravak, komplet ili proizvod za uporabu u skladu s bilo kojim od zahtjeva 1 do 5, naznačeni time što navedeni subjekt ima: (A) infekciju ili zaraznu bolest i izborno navedeni subjekt također ima cističnu fibrozu, poželjno gdje je infekcija ili zarazna bolest: (a) mikrobna infekcija ili mikrobna zarazna bolest, nadalje poželjno pri čemu je mikrobna infekcija ili mikrobna zarazna bolest: (i) bakterijska infekcija ili bakterijska zarazna bolest, poput sepse, bakterijskog meningitisa, bakterijske upale pluća, čira na želucu, legioneloze, hripavca, salmoneloze ili tuberkuloze; ili (ii) gljivična infekcija ili gljivična zarazna bolest; (b) virusna infekcija ili virusna zarazna bolest, poput AIDS-a/HIV-a, Denga groznice, ospica, zaušnjaka, rubeole, gripe ili hepatitisa; ili (c) parazitska infekcija ili parazitska zarazna bolest, poput malarije, toksoplazmoze, tripanosomijaze ili šistosomijaze; (B) upalnu bolest ili autoimunu bolest; ili (C) traumu, poželjno gdje je navedena trauma uzrokovana ozljedom ili operativnim zahvatom, nadalje poželjno kada navedena trauma uzrokovana ozljedom je politrauma, trauma glave, trauma prsa, trauma trbuha ili trauma ekstremiteta i/ili opeklina.
7. Sredstvo, pripravak, komplet ili proizvod za uporabu u skladu s bilo kojim od zahtjeva 1 do 4, naznačeni time što navedeni subjekt ima bolest presadka naspram domaćina (GVHD).
8. Sredstvo, pripravak, komplet ili proizvod za uporabu u skladu s bilo kojim od zahtjeva 1 do 7, naznačeni time što sredstvo ili pripravak rezultira smanjenjem jednog ili više citokina ili kemokina odabranih iz bilo kojeg ili više TNFα, IL1RA, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8 (CXCL8), IL-9, IL-10, IL-12, IL-13, IL-15, IL-17, CCL11, osnovniFGF, G-CSF, GM-CSF, INFγ, CXCL10, CCL2, CCL3, CCL4, PDGF-β, CCL5 i VEGF.
9. Sredstvo, pripravak, komplet ili proizvod za uporabu u skladu s bilo kojim od zahtjeva 1 do 8, naznačeni time što X3 i/ili X4 je serin (S) ili treonin (T).
10. Sredstvo, pripravak, komplet ili proizvod za uporabu u skladu s bilo kojim od zahtjeva 1 do 9, naznačeni time što PCNA motiv interakcije sadrži sekvencu odabranu između: [R/K/H]-[W/F/Y]-[L/I/V/A/M/S/T/N/Q]-[V/L/I/A/M/G/S/T/N/Q/R/H/K]-[K/R/H/P] (SEQ ID NO: 3); [R/K/H]-[W/F/Y]-[L/I/V/A/M/S/T]-[V/L/I/A/M/G/S/T/N/Q/R/H/K]-[K/R/H/P] (SEQ ID NO: 4); [R/K/H]-[W/F/Y]-[L/I/V/A/M/S/T]-[V/L/I/A/M/G/S/T/N/Q/R/H/K]-[K/R/H] (SEQ ID NO: 5); [R/K/H]-[W/F/Y]-[L/I/V/A/M/S/T]-[V/L/I/A/M/G/S/T/R/K]-[K/R/H] (SEQ ID NO: 6); [R/K/H]-[W/F/Y]-[L/I/V/A/M/S/T]-[V/L/I/A/M/G/S/T]-[K/R/H] (SEQ ID NO: 7); [R/K]-[W/F/Y]-[L/I/V/A/M/S/T]-[V/L/I/A/M/G/S/T]-[K/R] (SEQ ID NO: 8); [R/K]-[W/F]-[L/I/V/A/M/S/T]-[V/L/I/A/M/G/S/T]-[K/R] (SEQ ID NO: 9); [R/K]-[W/F]-[L/I/V/A/M/T]-[V/L/I/A/M/G/S/T]-[K/R] (SEQ ID NO: 10); [R/K]-[W/F]-[L/I/V/A/M/T]-[V/L/I/A/M/S/T]-[K/R] (SEQ ID NO: 11); [R/K]-[VV/F]-[L/I/V/A/M/S/T]-[V/L/I/A/M/G]-[K/R] (SEQ ID NO: 12); [R/K]-[W/F]-[L/I/A/V/M/T]-[V/L/I/A/M/S/T]-[K/R] (SEQ ID NO: 13); [R/K]-[W/F]-[L/I/V/A/M/S/T]-[V/L/A/I/S/T]-[K/R] (SEQ ID NO: 14); [R/K]-[W/F]-[L/V/I/A/T]-[V/L/A/I/S/T]-[K/R] (SEQ ID NO: 15); [R]-[W/F/Y]-[L/V/I/A]-[V/L/A/S/T/M]-[K/R] (SEQ ID NO: 16); [R]-[W/F/Y]-[L/V/I/A/T]-[V/L/A/S/T/M]-[K] (SEQ ID NO: 17); [R/K]-[F/Y]-[L/V/I/A]-[V/L/A/I/M]-[K/R] (SEQ ID NO: 18); [R/K]-[W/F/Y]-[L/I/V/A]-[V/L/I/A]-[K/R] (SEQ ID NO: 19); [R/K]-[W/Y]-[L/V/I/A/S/T]-[V/L/A/S/T/M]-[K/R] (SEQ ID NO: 20); ili [K]-[F/Y/W]-[I/L/V/A/T]-[V/L/A/I/S/T/M]-[K] (SEQ ID NO: 21).
11. Sredstvo, pripravak, komplet ili proizvod za uporabu u skladu s bilo kojim od zahtjeva 1 do 10, naznačeni time što PCNA motiv interakcije sadrži sekvencu odabranu iz bilo koje od SEQ ID NO: 22 do 297 ili 1209.
12. Sredstvo, pripravak, komplet ili proizvod za uporabu u skladu s bilo kojim od zahtjeva 1 do 11, naznačeni time što: (a) X1 i X2 su RW, RF, KF, KW, RY ili KY; i/ili (b) X3 i X4 su LV, LL, LA, AL, VL, VI, LI, IL, VV, VA, IV, II, AV, IA, AI, AM, LM, LS, LT, IS, MV, TV, AA, IM, LN, LQ, VM, TL, SL, IT, VT, LG, MA, ML, NL, QL, QI, TI, SI, AS, VS, SV, CA, IG, LR, VR, TK ili IR; i/ili (c) X3 i X4 nisu AG, AC, CC, NN, QQ, NQ, QN, TS, SS, ST ili TT.
13. Sredstvo, pripravak, komplet ili proizvod za uporabu u skladu s bilo kojim od zahtjeva 1 do 12, naznačeni time što je CPP odabran iz bilo kojeg od sljedećih: (i) peptida klase antenapedije; (ii) peptida klase protegrina; (iii) peptida klase HIV-TAT; (iv) peptida amfipatičke klase odabranog između amfipatičkog i mrežnog pozitivno nabijenog peptida, prolinernog amfipatičkog peptida, peptida na osnovi Pep-1 peptida i peptida na osnovi MPG peptida; (v) peptida koji pokazuje visok sadržaj α-spirala; (vi) peptida koji sadrži oligomere osnovnih aminokiselina; (vii) pVEC-a; (viii) peptida izvedenog iz kalcitonina; i (ix) amfifilnog cikličnog CPP-a, poželjno gdje je CPP odabran iz bilo koje od SEQ ID NO: 337, 302 do 336, 338 do 1162, ili 1210 do 1220 ili njegov fragment i/ili derivat i/ili gdje sredstvo nadalje sadrži vezujuću domenu, poželjno gdje vezujuća domena sadrži signalnu sekvencu nuklearne lokalizacije, nadalje poželjno kada vezujuća domena ili signalna sekvenca nuklearne lokalizacije sadrži sekvencu odabranu iz bilo kojeg od: (i) peptida od 4-20 aminokiselina, pri čemu su najmanje 4 aminokiseline pozitivno nabijene aminokiseline, poželjno odabrane između K, R ili H; i/ili (ii) sekvence odabrane iz bilo koje od SEQ ID NO: 1176, 1163 do 1175 ili 1177 do 1181 ili njezinog fragmenta i/ili derivata, poželjno gdje vezujuća domena ili signalna sekvenca nuklearne lokalizacije sadrži sekvencu odabranu iz bilo koje od SEQ ID NO: 1163-1181 ili njezinog fragmenta i/ili derivata, poželjno gdje navedeni fragment i/ili derivat sadrži najmanje 4 pozitivno nabijene aminokiseline, poželjno odabrane između K, R ili H.
14. Sredstvo, pripravak, komplet ili proizvod za uporabu u skladu s bilo kojim od zahtjeva 1 do 13, naznačeni time što sredstvo sadrži PCNA motiv interakcije kako je navedeno u SEQ ID NO: 28, veznik ili signalnu sekvencu nuklearne lokalizacije kako je navedeno u SEQ ID NO: 1176 i signalnu sekvencu koja prodire u stanicu kako je navedeno u SEQ ID NO: 337 i/ili gdje sredstvo sadrži sekvencu kako je navedeno u bilo kojoj od SEQ ID NO: 1198, 1182 do 1197, 1199 do 1204 ili 1208.
15. Sredstvo, pripravak, komplet ili proizvod za uporabu u skladu s bilo kojim od zahtjeva 1 do 14, naznačeni time što sredstvo sadrži sekvencu kako je navedeno u SEQ ID NO: 1198, 1203, 1204 ili 1208.
HRP20210792TT 2013-11-06 2021-05-17 Imunosupresivna sredstva i njihova uporaba u terapiji HRP20210792T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1319620.9A GB201319620D0 (en) 2013-11-06 2013-11-06 Immunosuppressive agents and their use in therapy
EP14793594.4A EP3065759B1 (en) 2013-11-06 2014-11-06 Immunosuppressive agents and their use in therapy
PCT/EP2014/073966 WO2015067712A1 (en) 2013-11-06 2014-11-06 Immunosuppressive agents and their use in therapy

Publications (1)

Publication Number Publication Date
HRP20210792T1 true HRP20210792T1 (hr) 2021-08-20

Family

ID=49767770

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20210792TT HRP20210792T1 (hr) 2013-11-06 2021-05-17 Imunosupresivna sredstva i njihova uporaba u terapiji

Country Status (11)

Country Link
US (2) US10517923B2 (hr)
EP (1) EP3065759B1 (hr)
DK (1) DK3065759T3 (hr)
ES (1) ES2869901T3 (hr)
GB (1) GB201319620D0 (hr)
HR (1) HRP20210792T1 (hr)
LT (1) LT3065759T (hr)
PL (1) PL3065759T3 (hr)
PT (1) PT3065759T (hr)
RS (1) RS62047B1 (hr)
WO (1) WO2015067712A1 (hr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018140863A1 (en) * 2017-01-27 2018-08-02 Vanderbilt University Fused in sarcoma (fus) nuclear translocation inhibitors for preventing fibrosis
GB201319621D0 (en) * 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Antimicrobial agents and their use in therapy
GB201319620D0 (en) * 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Immunosuppressive agents and their use in therapy
GB201507722D0 (en) 2015-05-06 2015-06-17 Norwegian Univ Sci & Tech Ntnu Anti-bacterial agents and their use in therapy
GB201507721D0 (en) * 2015-05-06 2015-06-17 Norwegian Univ Sci & Tech Ntnu Immunosuppressive agents and their use in therapy
EP3432908A4 (en) * 2016-03-21 2020-07-29 Rhode Island Council on Postsecondary Education PEPTIDES SENSITIVE TO PH
WO2020138674A1 (ko) * 2018-12-26 2020-07-02 (주)케어젠 근육 이완용 조성물
MX2020014330A (es) * 2018-12-26 2021-03-09 Caregen Co Ltd Composicion para relajacion muscular.
KR102456989B1 (ko) * 2020-06-12 2022-10-21 (주)케어젠 항비만 활성을 가지는 디옥시콜산-펩타이드 결합체 및 이의 용도
KR102570768B1 (ko) * 2020-06-12 2023-08-28 (주)케어젠 펜타펩타이드를 유효성분으로 포함하는 다한증 치료용 조성물
KR102483938B1 (ko) * 2020-06-12 2023-01-04 (주)케어젠 펜타펩타이드를 유효성분으로 포함하는 항알러지 또는 아토피피부염 개선용 조성물
CN115916236A (zh) * 2020-06-12 2023-04-04 凯尔格恩有限公司 包含五肽作为活性成分的组合物
KR102469721B1 (ko) * 2020-06-12 2022-11-23 (주)케어젠 보툴리눔 톡신 유사 활성을 갖는 펩타이드 및 이의 용도
KR102463320B1 (ko) * 2020-06-12 2022-11-07 (주)케어젠 펜타펩타이드를 유효성분으로 포함하는 통증의 완화, 예방 또는 치료용 조성물
US11741686B2 (en) 2020-12-01 2023-08-29 Raytheon Company System and method for processing facility image data

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198541A (en) 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
US6316003B1 (en) * 1989-12-21 2001-11-13 Whitehead Institute For Biomedical Research Tat-derived transport polypeptides
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
EP0642579B1 (en) 1992-05-19 1999-04-07 Xoma Corporation Improved methods for the preparation of endotoxin-binding proteins
US5420019A (en) 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
ES2123134T3 (es) 1993-03-12 1999-01-01 Xoma Corp Peptidos biologicamente activos de dominios funcionales de la proteina bactericida aumentadora de la permeabilidad y usos de los mismos.
MX9401807A (es) 1993-03-12 1995-01-31 Xoma Corp Usos terapeuticos de productos de proteina que incrementan lapermeabilidad/bactericidas.
AU7970894A (en) 1993-10-15 1995-05-04 Xoma Corporation Method of treating depressed reticuloendothelial system function
MX9602570A (es) 1994-01-14 1997-04-30 Xoma Corp Metodos y materiales anti-fungosos.
AU703192B2 (en) 1994-01-14 1999-03-18 Xoma Corporation Anti-gram-positive bacterial methods and materials
US5643875A (en) 1994-01-24 1997-07-01 Friedmann; Nadav Human therapeutic uses of bactericidal/permeability increasing (BPI) protein products
US5447913A (en) 1994-03-11 1995-09-05 Xoma Corporation Therapeutic uses of bactericidal/permeability-increasing protein dimer products
US5578568A (en) 1994-04-22 1996-11-26 Xoma Corporation Method of treating conditions associated with intestinal ischemia/reperfusion
US5646114A (en) 1994-07-11 1997-07-08 Xoma Corporation Anti-protozoan methods
AU709738B2 (en) 1994-09-15 1999-09-02 Xoma Corporation Anti-fungal peptides
US5912228A (en) 1995-01-13 1999-06-15 Xoma Corporation Therapeutic compositions comprising bactericidal/permeability-increasing (BPI) protein products
US5494896A (en) 1995-03-31 1996-02-27 Xoma Corporation Method of treating conditions associated with burn injuries
US6057291A (en) * 1995-06-02 2000-05-02 University Of British Columbia Antimicrobial cationic peptides
EP0839156A1 (en) 1995-07-20 1998-05-06 Xoma Corporation Anti-fungal peptides
US5686414A (en) 1995-11-14 1997-11-11 Xoma Corporation Methods of treating conditions associated with corneal transplantation
US5851802A (en) 1996-03-22 1998-12-22 Xoma Corporation Methods for recombinant microbial production of fusion proteins and BPI-derived peptides
NZ332720A (en) 1996-05-10 2000-07-28 Xoma Corp Therapeutic uses of bactericidal/permeability increasing (BPI) protein to treat human meningococcemia
US5741779A (en) 1996-05-10 1998-04-21 Xoma Corporation Antithrombotic materials and methods
AU736096B2 (en) 1996-05-23 2001-07-26 Xoma Corporation Therapeutic uses of BPI protein products in humans with hemorrhage due to trauma
US5888973A (en) 1996-08-09 1999-03-30 Xoma Corporation Anti-chlamydial uses of BPI protein products
EP0938331B1 (en) 1996-11-01 2002-12-18 XOMA Technology Ltd. Therapeutic uses of bpi protein products in cystic fibrosis patients
US6482796B2 (en) 1996-11-01 2002-11-19 Xoma Corporation Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients
US6093573A (en) 1997-06-20 2000-07-25 Xoma Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
US6013631A (en) 1998-06-19 2000-01-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
SE512161C2 (sv) 1998-06-30 2000-02-07 Sandvik Ab Hårdmetall och användning av denna vid olje- och gasutvinning
AU6163099A (en) 1998-09-25 2000-04-17 Xoma Technology Ltd. Antifungal and antibacterial peptide
WO2000043028A2 (en) 1999-01-22 2000-07-27 Xoma Technology Ltd. Method of treating chronic cardiac disease
US6153584A (en) 1999-04-01 2000-11-28 Levy; Ofer Therapeutic uses of BPI protein products in BPI-deficient humans
US6355616B1 (en) 1999-06-25 2002-03-12 Xoma (Us) Technology Ltd. Derivative compounds derived from or based on bactericidal/permeability-increasing protein
AU4203900A (en) 1999-07-12 2001-01-30 Xoma Technology Ltd. Method to identify antimicrobial agents
WO2001003724A1 (en) 1999-07-12 2001-01-18 Xoma Technology Ltd. Therapeutic uses of bpi protein products for inhibiting h+/k+ atpase activity
AU4204800A (en) 1999-07-12 2001-01-30 Xoma Technology Ltd. Method to identify inhibitors f1/f0 atpase
WO2001004348A1 (en) 1999-07-12 2001-01-18 Xoma Technology Ltd. Methods to identify inhibitors of f1/f0 atpase
US6777439B2 (en) * 2000-05-30 2004-08-17 Advanced Research & Technology Institute, Inc. Compositions and methods for identifying agents which modulate PTEN function and PI-3 kinase pathways
US20030166528A1 (en) 2000-10-11 2003-09-04 Jong-Jye Lin Antifungal compound
AU2002241589B2 (en) 2000-12-01 2007-07-19 Xoma Technology Ltd. Modulation of pericyte proliferation using BPI protein products or BPI inhibitors
JP4310107B2 (ja) 2001-03-28 2009-08-05 ヘリックス バイオメディックス，インコーポレイテッド 生物活性を有する短ペプチド及び該ペプチドの使用方法
US7517857B2 (en) 2002-01-29 2009-04-14 Posco Immune-modulating peptide
WO2005068504A1 (ja) * 2004-01-19 2005-07-28 Medical And Biological Laboratories Co., Ltd. 炎症性サイトカイン抑制剤
KR20080023680A (ko) * 2005-05-10 2008-03-14 인터뮨, 인크. 스트레스-활성화 단백질 키나제 시스템을 조절하기 위한피리돈 유도체
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US7579318B2 (en) * 2005-12-06 2009-08-25 Centre De La Recherche De La Scientifique Cell penetrating peptides for intracellular delivery of molecules
US20110038856A1 (en) * 2006-11-02 2011-02-17 Seattle Genetics, Inc. Methods of treating neoplastic, autoimmune and inflammatory diseases
US8419332B2 (en) * 2007-10-19 2013-04-16 Atlas Bolt & Screw Company Llc Non-dimpling fastener
GB0803352D0 (en) * 2008-02-22 2008-04-02 Ntnu Technology Transfer As Oligopeptidic compounds and uses thereof
CA2744120A1 (en) * 2008-11-17 2010-05-20 The Provost, Fellows, Foundation Scholars, And The Other Members Of Boar D, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, A vaccinia virus protein a46 peptide and use thereof
GB0916576D0 (en) * 2009-09-22 2009-10-28 Malmsten Nils M Polypeptides and uses thereof
AT510991A5 (de) * 2009-10-09 2015-02-15 Kemijski Inst Peptide für die Inhibition MyD88-abhängiger Signalwege
WO2011104309A1 (en) * 2010-02-24 2011-09-01 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compounds for the treatment of inflammation and neutropenia
WO2012154814A1 (en) * 2011-05-09 2012-11-15 Eip Pharma, Llc Compositions and methods for treating alzheimer's disease
WO2012177892A2 (en) * 2011-06-21 2012-12-27 University Of Florida Research Foundation, Inc. Type i interferon mimetics as therapeutics for cancer, viral infections, and multiple sclerosis
CA2878701C (en) * 2011-07-12 2022-05-17 The University Of British Columbia Neuroprotective pepties that inhbit interaction between palmitoyl acyl transferase zinc-finger dhhc type containing 17 (zd17) and c-jun n-terminal kinase (jnk)
WO2013110005A1 (en) * 2012-01-18 2013-07-25 Wisconsin Alumni Research Foundation Boronate-mediated delivery of molecules into cells
KR101497972B1 (ko) * 2012-03-21 2015-03-03 서울대학교산학협력단 Ｎｏｄ2 신호전달 경로를 표적으로 하는 패혈증 치료제 스크리닝 방법 및 패혈증 치료제
GB201319621D0 (en) * 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Antimicrobial agents and their use in therapy
GB201319620D0 (en) * 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Immunosuppressive agents and their use in therapy

Also Published As

Publication number Publication date
GB201319620D0 (en) 2013-12-18
WO2015067712A1 (en) 2015-05-14
DK3065759T3 (da) 2021-05-17
US11246907B2 (en) 2022-02-15
EP3065759A1 (en) 2016-09-14
US10517923B2 (en) 2019-12-31
EP3065759B1 (en) 2021-03-31
LT3065759T (lt) 2021-08-10
US20200323953A1 (en) 2020-10-15
PT3065759T (pt) 2021-05-17
US20160279193A1 (en) 2016-09-29
PL3065759T3 (pl) 2021-10-25
ES2869901T3 (es) 2021-10-26
RS62047B1 (sr) 2021-07-30

Similar Documents

Publication Publication Date Title
HRP20210792T1 (hr) Imunosupresivna sredstva i njihova uporaba u terapiji
RU2013154706A (ru) Модифицированный биотин-связывающий белок, слитые белки на его основе и их применение
JP2018510622A5 (hr)
CY1122691T1 (el) Πρωτεϊνες δεσμευσης αλβουμινης ορου
JP2018528253A5 (hr)
JP2014224126A5 (hr)
RU2016120641A (ru) Новые полипептиды
RU2021120582A (ru) Мутации фермента crispr, уменьшающие нецелевые эффекты
HRP20181055T1 (hr) Antagonisti kv1.3 i postupci upotrebe
JP2014500714A5 (hr)
JP2018527933A (ja) 新規なエンドリシンポリペプチド
JP2014528906A5 (hr)
JP2012530510A5 (hr)
HRP20211601T1 (hr) Rekombinantni proteini bez fenilalanina (phe) za liječenje fenilketonurije
TR201908150T4 (tr) Peptitler ve kullanımları.
RU2015103816A (ru) ПРОНИКАЮЩИЕ В КЛЕТКУ ПЕПТИДЫ, МИШЕНЬЮ КОТОРЫХ ЯВЛЯЕТСЯ eIF4E
RU2014140231A (ru) Антимикробные пептиды
JP2015521206A5 (hr)
JP2014526881A5 (hr)
JP2016501266A5 (hr)
BR112015013387B8 (pt) Proteínas tipo coiled-coil modificadas possuindo propriedades melhoradas
BR112022010153A2 (pt) Peptídeos, ácido nucleico, polipeptídeo, composição, complexo bioluminescente, métodos, dipeptídeo, sistema e kit
JP2015533791A5 (hr)
WO2021046549A8 (en) Compositions and methods for the treatment of viral infections
JP2019505567A5 (hr)